Clinicopathologic Conference, Plasm-Cell Myeloma Post-Transplant Lymphoproliferative Disorder
NEJM 386:2508-2516, Case 20-2022, 2022
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Stroke in Patients with Bacterial Meningitis:A Cohort Study and Meta-Analysis
Ann Neurol 93:1094-1105, Beuker,C.,et al, 2023
Clinicopathological Conference, Chronic Candida Albicans Meningitis
NEJM 387:641-650, Case 25-2022, 2022
Clinicopathologic Conference, Fat Embolism Syndrome
NEJM 385:2464-2474, Case 39-2021, 2021
Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020
Chemotherapy-Associated Hyperammonemic Encephalopathy
Neurol 94:e874-e877, Briard, J.N.,et al, 2020
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients
Am J Kidney Dis PMID:31040091, Seethapathy, H. & Fenves, A.Z., 2019
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
A 45-year-old man with Weakness and Myalgia after Orthopedic Surgery
Neurol 88:e185-e189, Vazquez do Campo, R.,et al, 2017
Idiopathic Hyperammonemia after Solid Organ Transplantation: Primarily a Lung Problem? A Single-Center Experience and Systematic Review
ClinTransplant 31:e12957, Krutsinger, D.,et al, 2017
Clinicopathologic Conference, Somnolence due to the Cerebral Fat Embolism Syndrome
NEJM 375:370-378, Case 23-2016, 2016
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Risk Factors of Hyperammonemia in Patients with Epilepsy Under Valproic Acid Therapy
Medicine 93:e66, Tseng, Y.L.,et al, 2014
Enhancing Brain Lesions after Endovascular Treatment of Aneurysms
AJNR 35:1954-1958, Cruz, J.P.,et al, 2014
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Serum Creatinine May Indicate Risk of Symptomatic Intracranial Hemorrhage after Intravenous Tissue Plasminogen Activator (IV tPA)
Medicine 92:317-323, Marsh, E.B.,et al, 2013
Glycosylated Hemoglobin A1 Predicts Risk for Symptomatic Hemorrhage After Thrombolysis for Acute Stroke
Stroke 44:2134-2138, Rocco, A.,et al, 2013
Combined Retinal and Cerebral Hyperperfusion Syndrome after Carotid Thromboendarterectomy
Neurol 81:e166-e167, Ketteler, S.,et al, 2013
Insulin for Glycemic Control in Acute Ischemic Stroke
Stroke 43:e29, Bellolio,M.F.,et al, 2012
Asymmetric Pattern of Cerebrovascular Lesions in Patients after Left Ventricular Assist Device Implantation
Stroke 43:872-874, Kato,T.S.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Clinical and MRI characteristics of acute migrainous infarction
Neurol 76:1911-1917, Wolf, M.E.,et al, 2011
Assessing Bioequivalence of Generic Antiepilepsy Drugs
Ann Neurol 70:221-228,192, Krauss, G.L.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Intraventricular Hemorrhage
UpToDate, Sept, Cucchiara B.L. and Pacelli, J.P., 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Functional Contrast-Enhanced CT for Evaluation of Acute Ischemic Stroke Does not Increase the Risk of Contrast-Induced Nephropathy
AJNR 31:817-821, Lima,F.O., et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Generic Substitution in the Treatment of Epilepsy: Case Evidence of Breakthrough Seizures
Neurol 71:525-530, Berg,M.J.,et al., 2008
Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage
Arch Neuol 65:1313-1318, Claassen,D.O.,et al, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008